JP7617012B2 - Ｃ５ａＲを標的とする抗体 - Google Patents

Ｃ５ａＲを標的とする抗体 Download PDF

Info

Publication number
JP7617012B2
JP7617012B2 JP2021554761A JP2021554761A JP7617012B2 JP 7617012 B2 JP7617012 B2 JP 7617012B2 JP 2021554761 A JP2021554761 A JP 2021554761A JP 2021554761 A JP2021554761 A JP 2021554761A JP 7617012 B2 JP7617012 B2 JP 7617012B2
Authority
JP
Japan
Prior art keywords
seq
antibody
region
human
antibody fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021554761A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022524449A5 (enExample
JP2022524449A (ja
Inventor
ジュリア・ノイゲバウアー
バーバラ・バッハラー－コネッキー
タニヤ・ヘルマン
ヴィンフリート・エリス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Morphosys GmbH
Original Assignee
Morphosys GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys GmbH filed Critical Morphosys GmbH
Publication of JP2022524449A publication Critical patent/JP2022524449A/ja
Publication of JP2022524449A5 publication Critical patent/JP2022524449A5/ja
Priority to JP2025001775A priority Critical patent/JP7842914B2/ja
Application granted granted Critical
Publication of JP7617012B2 publication Critical patent/JP7617012B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2021554761A 2019-03-14 2020-03-13 Ｃ５ａＲを標的とする抗体 Active JP7617012B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025001775A JP7842914B2 (ja) 2019-03-14 2025-01-06 Ｃ５ａＲを標的とする抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19162759 2019-03-14
EP19162759.5 2019-03-14
PCT/EP2020/056754 WO2020182974A1 (en) 2019-03-14 2020-03-13 Antibodies targeting c5ar

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025001775A Division JP7842914B2 (ja) 2019-03-14 2025-01-06 Ｃ５ａＲを標的とする抗体

Publications (3)

Publication Number Publication Date
JP2022524449A JP2022524449A (ja) 2022-05-02
JP2022524449A5 JP2022524449A5 (enExample) 2023-03-17
JP7617012B2 true JP7617012B2 (ja) 2025-01-17

Family

ID=65812165

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021554761A Active JP7617012B2 (ja) 2019-03-14 2020-03-13 Ｃ５ａＲを標的とする抗体
JP2025001775A Active JP7842914B2 (ja) 2019-03-14 2025-01-06 Ｃ５ａＲを標的とする抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025001775A Active JP7842914B2 (ja) 2019-03-14 2025-01-06 Ｃ５ａＲを標的とする抗体

Country Status (14)

Country Link
US (3) US20220135658A1 (enExample)
EP (1) EP3938393A1 (enExample)
JP (2) JP7617012B2 (enExample)
KR (1) KR102977518B1 (enExample)
CN (1) CN113574072B (enExample)
AU (1) AU2020235263B2 (enExample)
BR (1) BR112021017860A2 (enExample)
CA (1) CA3132771A1 (enExample)
IL (1) IL286238A (enExample)
MA (1) MA55285A (enExample)
MX (1) MX2021011040A (enExample)
SG (1) SG11202108761YA (enExample)
TW (1) TWI901581B (enExample)
WO (1) WO2020182974A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
WO2022057910A1 (en) * 2020-09-17 2022-03-24 I-Mab Biopharma Co., Ltd Combination therapies targeting c5ar and pd-1/pd-l1 pathways
US11912781B2 (en) * 2021-01-13 2024-02-27 Visterra, Inc. Humanized complement 5A receptor 1 antibodies and methods of use thereof
WO2024236163A1 (en) 2023-05-17 2024-11-21 Morphosys Ag T cell receptor beta constant region 2 (trbc2) antibodies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011515073A (ja) 2008-02-20 2011-05-19 ジーツー インフラメイション プロプライエタリー リミテッド ヒト化抗Ｃ５ａＲ抗体
JP2014523408A (ja) 2011-06-06 2014-09-11 ノヴォ ノルディスク アー／エス 治療抗体
WO2018234118A1 (en) 2017-06-23 2018-12-27 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of c5a activity

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
US6136599A (en) 1998-12-10 2000-10-24 Bayer Corporation Human hybrid host cell for mammalian gene expression
CA2347973C (en) 1999-07-20 2010-06-22 Morphosys Ag Novel methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds
US8071096B2 (en) * 2002-01-25 2011-12-06 G2 Therapies Ltd Anti-C5aR antibodies and uses thereof
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
KR101559599B1 (ko) * 2007-11-26 2015-10-12 바이엘 인텔렉쳐 프로퍼티 게엠베하 항-메소텔린 항체 및 이의 용도
AU2011245117B2 (en) * 2010-04-30 2015-03-12 Alexion Pharmaceuticals, Inc. Anti-C5a antibodies and methods for using the antibodies
LT2691417T (lt) 2011-03-29 2018-10-25 Roche Glycart Ag Antikūno fc variantai
DK2994488T3 (da) * 2013-05-08 2022-10-03 Novo Nordisk As Anvendelse af c5ar-antagonister
ES2736500T3 (es) 2014-06-18 2020-01-02 Morphosys Ag Proteínas de fusión y usos de las mismas

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011515073A (ja) 2008-02-20 2011-05-19 ジーツー インフラメイション プロプライエタリー リミテッド ヒト化抗Ｃ５ａＲ抗体
JP2014523408A (ja) 2011-06-06 2014-09-11 ノヴォ ノルディスク アー／エス 治療抗体
WO2018234118A1 (en) 2017-06-23 2018-12-27 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of c5a activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SPAAN, A. N. et al.，J Immunol.，2015年，195(3)，1034-1043

Also Published As

Publication number Publication date
US12018072B2 (en) 2024-06-25
JP2025069140A (ja) 2025-04-30
JP7842914B2 (ja) 2026-04-08
WO2020182974A1 (en) 2020-09-17
AU2020235263B2 (en) 2026-06-04
EP3938393A1 (en) 2022-01-19
US20220135658A1 (en) 2022-05-05
TW202041535A (zh) 2020-11-16
MA55285A (fr) 2022-01-19
US20240400657A1 (en) 2024-12-05
AU2020235263A1 (en) 2021-09-02
TWI901581B (zh) 2025-10-21
SG11202108761YA (en) 2021-09-29
BR112021017860A2 (pt) 2021-12-07
KR102977518B1 (ko) 2026-06-12
KR20210141988A (ko) 2021-11-23
US20240018225A1 (en) 2024-01-18
MX2021011040A (es) 2021-12-10
NZ778810A (en) 2025-10-31
JP2022524449A (ja) 2022-05-02
CN113574072A (zh) 2021-10-29
CN113574072B (zh) 2023-12-12
IL286238A (en) 2021-10-31
CA3132771A1 (en) 2020-09-17

Similar Documents

Publication Publication Date Title
JP7247238B2 (ja) イオン濃度依存的抗原結合ドメインを含む抗体、Ｆｃ領域改変体、ＩＬ－８に結合する抗体、およびその使用
KR102755473B1 (ko) 인간 il-4ra에 대한 항체 및 이의 용도
KR102257154B1 (ko) Pd-1 결합 단백질을 사용하는 면역 질환의 치료 방법
AU2015341884B2 (en) CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
JP7842914B2 (ja) Ｃ５ａＲを標的とする抗体
US12304957B2 (en) Anti-CD161 antibodies and uses thereof
KR101822702B1 (ko) G-csfr에 대한 항체 및 이의 용도
TW202237651A (zh) 靶向ＣＤ３９及ＴＧＦβ之新穎結合物分子
KR102709785B1 (ko) Ｉｌ－５ 항체, 이의 항원 결합 단편 및 이의 의학적 적용
US20250059288A1 (en) Antibodies targeting ccr2
CN116783220A (zh) 抗bcma抗体及其制备方法和应用
RU2823245C2 (ru) Антитела, нацеливающиеся на C5aR
CA3220167A1 (en) Anti-trem-1 antibodies
KR20230087552A (ko) Cd45를 다량체화하는 결합 분자
JP2023522027A (ja) 生合成糖タンパク質集団
HK40061359B (en) Antibodies targeting c5ar
HK40061359A (en) Antibodies targeting c5ar

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230308

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230308

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240527

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240729

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241024

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241202

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250106

R150 Certificate of patent or registration of utility model

Ref document number: 7617012

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02